Skip to content

Study · Systematic review · n = 218 · 2021

4 results

The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review.

Ghorbani Z, Mirghafourvand M

Post reproductive health19 Aug 2020Cited by 6 (Europe PMC)

PMID32814499 (opens in a new tab)DOI10.1177/2053369120946645 (opens in a new tab)PepBankPUB-32814499
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in postmenopausal women with vaginal atrophy, intravaginal oxytocin versus placebo gave a statistically significant result on cytological analysis.

    In plain wordsIn postmenopausal women with vaginal atrophy, vaginal oxytocin gave a significant result on cell tests compared with placebo. The abstract does not state the direction.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedCytological analysis of vaginal atrophy
    Study

    n = 218

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginalAs given in this study (human).

    Measurements

    Standardized mean difference
    35.13 SMD
    cytological analysis

    Source sentences

    Summary
    The meta-analysis in terms of the cytological analysis (standardized mean difference: 35.13, 95% confidence interval: 32.59-37.67, n = 218, I2 = 96%) was statistically significant.
    1 context sentence
    Summary · context
    Only randomized controlled trials that compared intravaginal oxytocin with placebos were included.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in postmenopausal women, intravaginal oxytocin versus placebo did not significantly change endometrial thickness.

    In plain wordsIn postmenopausal women, vaginal oxytocin did not change the thickness of the womb lining compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeEndometrial thickness
    Study

    n = 95

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginalAs given in this study (human).

    Measurements

    Standardized mean difference
    0.05 SMD
    endometrial thickness

    Source sentences

    Summary
    In terms of histological assessments (standardized mean difference: -0.38, 95% confidence interval: -0.94 to 0.17, n = 38, I2 = 0%) and endometrial thickness (standardized mean difference: 0.05, 95% confidence interval: -0.20 to -0.31, n = 95, I2 = 0…
    1 context sentence
    Summary · context
    Only randomized controlled trials that compared intravaginal oxytocin with placebos were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in postmenopausal women with vaginal atrophy, intravaginal oxytocin versus placebo did not significantly change histological assessments.

    In plain wordsIn postmenopausal women with vaginal atrophy, vaginal oxytocin did not change tissue test results compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeHistological assessment of vaginal atrophy
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginalAs given in this study (human).

    Measurements

    Standardized mean difference
    −0.38 SMD
    histological assessments

    Source sentences

    Summary
    In terms of histological assessments (standardized mean difference: -0.38, 95% confidence interval: -0.94 to 0.17, n = 38, I2 = 0%) and endometrial thickness (standardized mean difference: 0.05, 95% confidence interval: -0.20 to -0.31, n = 95, I2 = 0…
    1 context sentence
    Summary · context
    Only randomized controlled trials that compared intravaginal oxytocin with placebos were included.
  4. 04HumanSystematic reviewEfficacy outcome

    Three of the included randomized trials of intravaginal oxytocin reported a statistically significant improvement in subjective symptoms of vaginal atrophy; no meta-analysis was done.

    In plain wordsThree trials of vaginal oxytocin in postmenopausal women reported better symptoms. The review could not pool these results.

    Peptide
    Oxytocin
    Outcome
    Not applicableSubjective symptoms of vaginal atrophy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginalAs given in this study (human).

    Source sentences

    Summary
    Three studies reported a statistically significant improvement in the subjective symptoms
    1 context sentence
    Summary · context
    Only randomized controlled trials that compared intravaginal oxytocin with placebos were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.